Key result
In a real-life series of 33 patients with severe inherited thrombophilia, NOAC therapy was associated with a 9% rate of recurrent VTE over a median 21 months, mostly related to nonadherence.
Why the study?
Are non-vitamin K antagonist oral anticoagulants effective and safe in preventing recurrent VTE in patients with severe inherited thrombophilia?
Population
33 consecutive patients with severe inherited thrombophilia following venous thromboembolism.
Design
Case_series
Follow-up
median 21 (range 8-34) months
Authors
Loading...
Highlights adherence to minimize recurrent VTE with NOACs in thrombophilia; leaves open randomized confirmation.
Observational (n=33)
Are non-vitamin K antagonist oral anticoagulants effective and safe in preventing recurrent VTE in patients with severe inherited thrombophilia?
NOACs appear to be a safe and effective treatment option for patients with severe inherited thrombophilia following VTE, provided adherence is maintained.
Undas et al. (2017) conducted an observational in Severe inherited thrombophilia following venous thromboembolism (n=33). Non-vitamin K antagonist oral anticoagulants (NOACs) was evaluated on Recurrent VTE episodes. In a real-life series of 33 patients with severe inherited thrombophilia, NOAC therapy was associated with a 9% rate of recurrent VTE over a median 21 months, mostly related to nonadherence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: